We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Conduit Pharmaceuticals, Inc. is a disease agnostic life science company. The Company is engaged in the development and commercialization of clinical assets to address the unmet medical needs of patients. The Company¿s licensed clinical assets are focused on idiopathic male infertility and autoimmun... Conduit Pharmaceuticals, Inc. is a disease agnostic life science company. The Company is engaged in the development and commercialization of clinical assets to address the unmet medical needs of patients. The Company¿s licensed clinical assets are focused on idiopathic male infertility and autoimmune diseases or immunodeficient conditions like uveitis, preterm labor, renal transplant rejection and Hashimoto¿s Thyroiditis. The Company¿s asset pipeline includes AZD1656 (a Glucokinase Activator), and AZD5904 (a Myeloperoxidase Inhibitor). AZD1656 is a glucokinase activator used in diabetes mellitus. It is used as a treatment option for Hashimoto¿s Thyroiditis (HT) and Graves¿ disease, including investigating any negative side effects of the use of AZD1656 as compared with treatment options for Hashimoto¿s Thyroiditis and Graves¿ disease. AZD5904 includes a potent, irreversible inhibitor of human myeloperoxidase (MPO), that has the potential to treat Idiopathic Male Infertility (IMI). Show more
Conduit also appoints prominent intellectual property attorney Jeffrey Lindeman as a Consultant Leadership additions underscore Conduit’s commitment to strengthening and broadening its...
SAN DIEGO and LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit") today announced the opening of cutting-edge...
SAN DIEGO and LONDON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit"), a multi-asset, clinical-stage life science company delivering an efficient model...
SAN DIEGO and LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit Pharmaceuticals” or “Conduit”), a multi-asset clinical-stage disease-agnostic life...
SAN DIEGO and LONDON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit Pharmaceuticals” or “Conduit”), a multi-asset clinical-stage disease-agnostic life...
Presidio’s sponsored SPAC completed its previously announced business combination with Conduit Pharmaceuticals, Inc.Conduit now trades on the Nasdaq under ticker symbol “CDT” for its common stock...
SAN DIEGO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Limited (“Conduit Pharmaceuticals”), a multi-asset clinical-stage disease-agnostic life science company providing an...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.19 | 6.37583892617 | 2.98 | 3.21 | 2.92 | 13621 | 3.13791598 | CS |
| 4 | -0.62 | -16.3588390501 | 3.79 | 3.79 | 2.76 | 17650 | 3.18897174 | CS |
| 12 | 0.54 | 20.5323193916 | 2.63 | 3.92 | 2.41 | 32641 | 3.12006049 | CS |
| 26 | 1.83 | 136.567164179 | 1.34 | 7.7509 | 0.95 | 233070 | 2.69452476 | CS |
| 52 | -9.43 | -74.8412698413 | 12.6 | 12.89 | 0.95 | 233837 | 2.89708509 | CS |
| 156 | -9.43 | -74.8412698413 | 12.6 | 12.89 | 0.95 | 233837 | 2.89708509 | CS |
| 260 | -9.43 | -74.8412698413 | 12.6 | 12.89 | 0.95 | 233837 | 2.89708509 | CS |
Monksdream
4 weeks ago
goshavol
5 months ago
TheFinalCD
6 months ago
modrica3
6 months ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
